The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Loxo
Stock and Other Ownership Interests - Quintiles
Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.
 
Geoffrey R. Oxnard
Honoraria - Bio-Rad; Chugai Pharma; Guardant Health; Sysmex
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; DropWorks; Genentech/Roche; GRAIL; Ignyta; Inivata; LOXO; Novartis; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Alexander E. Drilon
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Ignyta; Loxo; Pfizer; Takeda; TP Therapeutics
 
Manisha H. Shah
Consulting or Advisory Role - Eisai; Loxo; Novartis
Research Funding - Eisai; Loxo; Merck
 
Lori J. Wirth
Consulting or Advisory Role - Amgen; Blueprint Medicines; Eisai; Loxo; Merck; Novartis
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Consulting or Advisory Role - Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Peleton (Inst); Pfizer (Inst); Principa Biopharma (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst)
 
Vamsidhar Velcheti
Honoraria - Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Merck; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Foundation Medicine; Genentech; Genoptix; Merck; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Foundation Medicine; Merck
 
Nehal J. Lakhani
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Amgen (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Forty Seven (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Inivata (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); OncoMed (Inst); Onxeo (Inst); ose pharma (Inst); ose pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca
 
Maria E. Cabanillas
Consulting or Advisory Role - Blueprint Medicines; Loxo
Research Funding - Eisai; Exelixis; Kura Oncology; Roche/Genentech
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Loxo; Novartis
Research Funding - Eisai; Plexxikon; Roche/Genentech
 
Kyle Gordon
Employment - Loxo
Stock and Other Ownership Interests - Gilead Sciences; Loxo
 
Steven Smith
Consulting or Advisory Role - Loxo
 
Michele Nguyen
Employment - Loxo
Stock and Other Ownership Interests - Loxo; Loxo
Travel, Accommodations, Expenses - Loxo
 
Edward Zhu
No Relationships to Disclose
 
Stephen M. Rothenberg
Employment - Loxo
Stock and Other Ownership Interests - Loxo
 
Kevin Ebata
Employment - Loxo
Stock and Other Ownership Interests - Loxo
 
Brian Benjamin Tuch
Employment - Loxo
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Karyopharm Therapeutics; Parity Computing
Patents, Royalties, Other Intellectual Property - Biomarkers for NTRK inhibition Biomarkers for proteasome inhibition
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar